Does the CCL2 rs1024611 AG genotype increase CCL2 expression and monocyte recruitment?

Context and Biological Background

The chemokine C-C motif ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1), plays an essential role in the recruitment and migration of monocytes into inflamed tissues. The CCL2 gene contains a well-studied single-nucleotide polymorphism (SNP) in its promoter region, designated as rs1024611 (often referred to mathematically as -2518 A>G). In individuals with the G allele (including the heterozygous AG genotype), this genetic variation acts as a cis-regulatory expression quantitative trait locus (eQTL) that influences how the gene is transcribed.

---

Evidence-Based Assessment

1. Genetic Mechanisms of Increased CCL2 Expression

• Allelic Expression Imbalance: Laboratory and genetic studies show that the G allele of the rs1024611 polymorphism is in strong linkage disequilibrium with other genetic variants, specifically the rs13900T variant in the 3' untranslated region (3'UTR). This specific genetic haplotype increases the stability of the messenger RNA (mRNA) by enhancing its binding to the RNA-binding protein HuR.
• Elevated Transcription: As a result of this increased mRNA stability and enhanced transcriptional activity, individuals with the AG genotype possess a molecular predisposition to produce more CCL2/MCP-1 compared to those with the homozygous wild-type AA genotype.

2. Monocyte-Recruitment Tendency and Chemotaxis

• Cellular Recruitment: CCL2 is a primary chemoattractant for monocytes. Elevated levels of this protein bind to its cognate receptor, CCR2, on the surface of monocytes. This interaction activates intracellular signaling cascades, upregulating beta-2 integrins (such as LFA-1 and Mac-1) on the monocyte membrane, which promotes their firm adhesion to the endothelial lining of blood vessels.
• Transendothelial Migration: The resulting concentration gradient guides these adherent monocytes to transmigrate through the vascular wall into subendothelial spaces. Consequently, the genetically driven increase in CCL2 expression directly translates to an enhanced physical tendency for monocytes to recruit and migrate to sites of active signaling.

3. Correlation with Circulating Monocyte Levels

• Mechanistic Plausibility: Animal models and genetic knock-out studies demonstrate a clear causal role for the CCL2-CCR2 axis in mobilizing monocytes from the bone marrow reserve into the bloodstream. Humans with rare, loss-of-function mutations in the CCR2 receptor gene present with significantly lower circulating monocyte counts, verifying the biology of this pathway.
• Clinical Dissociation: Despite this clear mechanistic pathway, large-scale human observational cohorts show a distinct "decoupling" between circulating CCL2 levels and absolute peripheral monocyte counts. In clinical studies of patients with cardiovascular risk factors (such as type 1 diabetes or established carotid atherosclerosis), elevations in local or systemic CCL2 do not consistently correlate with a higher absolute number of circulating monocytes. This suggests that while CCL2 dictates the movement and activation of these cells toward tissues, it is not the sole determinant of steady-state, baseline peripheral blood monocyte counts in healthy or chronically ill individuals.

4. Vascular-Inflammatory and Cardiovascular Risk

• Pathological Cascade: The recruitment of monocytes into the arterial intima is a foundational step in atherogenesis. Once inside the vessel wall, monocytes differentiate into macrophages, engulf oxidized lipids to become foam cells, and secrete pro-inflammatory cytokines that destabilize plaques.
• Epidemiological and Genetic Evidence: Mendelian randomization studies show that genetically predicted, lifetime elevation of circulating CCL2 (MCP-1) is causally associated with an increased risk of coronary artery disease (CAD), myocardial infarction, and ischemic stroke. While some intermediate subclinical markers (like carotid intima-media thickness) show variable direct correlation with the rs1024611 genotype itself, circulating CCL2/MCP-1 levels remain a robust, independent biomarker of subclinical atherosclerosis and subsequent adverse cardiovascular events.

---

Bottom Line

The claim is largely accurate and biologically supported. The CCL2 rs1024611 AG genotype increases CCL2 expression via enhanced mRNA stability, which subsequently increases the chemotactic pull and recruitment of monocytes to vascular endothelial walls, driving vascular-inflammatory and cardiovascular risk. However, while this axis dictates the recruitment and trafficking of inflammatory cells, human clinical data show that elevated CCL2 levels do not reliably correspond to a simple increase in the absolute count of circulating monocytes in the bloodstream.